Literature DB >> 7893837

The surgical treatment of patients with prosthetic valve endocarditis.

T E David1.   

Abstract

Prosthetic valve endocarditis is associated with high mortality and morbidity. Although antibiotics alone may sterilize an infected prosthetic valve, adjunctive surgical therapy is often necessary. Depending on the virulence of the offending microorganism, the type of prosthetic valve and the site where it was implanted, the infection spreads into paravalvular structures, producing abscess. Systemic embolization of infected material may cause metastatic abscess. Thus, timing of surgery in these patients is crucial to optimize clinical results. An aggressive approach is justifiable in most patients with prosthetic valve endocarditis. It is believed that radical resection of all infected material and reconstruction of the heart and annuli with fresh autologous or glutaraldehyde-fixed bovine pericardium offer the best chance to eradicate the infection. Prolonged antibiotic therapy is also necessary in these patients. In the author's personal experience with 45 patients with prosthetic valve endocarditis, the infection was limited to the valve in 10 patients and had extended into the surrounding tissues in 35. The operative mortality rate was 13%. The actuarial survival at 5 years was 61% +/- 5%. These results support the premise that radical resection of all infected materials offers a good chance for curing prosthetic valve endocarditis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7893837

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  14 in total

1.  Early and late outcomes after reoperation for prosthetic valve endocarditis.

Authors:  Y Sasaki; F Isobe; S Kinugasa; K Iwata; K Nagamachi; Y Kato; H Arimoto; H Hata
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-04

Review 2.  Current usage and future directions for the bovine pericardial patch.

Authors:  Xin Li; Yuanyuan Guo; Kenneth R Ziegler; Lynn S Model; Sammy D D Eghbalieh; Robert A Brenes; Susun T Kim; Chang Shu; Alan Dardik
Journal:  Ann Vasc Surg       Date:  2011-01-28       Impact factor: 1.466

Review 3.  Patches for carotid artery endarterectomy: current materials and prospects.

Authors:  Akihito Muto; Toshiya Nishibe; Herbert Dardik; Alan Dardik
Journal:  J Vasc Surg       Date:  2009-07       Impact factor: 4.268

4.  Pretreatment of pericardial patches with antibiotics does not alter patch healing in vivo.

Authors:  Hualong Bai; Go Kuwahara; Mo Wang; Kirstyn E Brownson; Trenton R Foster; Kota Yamamoto; Ying Xing; Alan Dardik
Journal:  J Vasc Surg       Date:  2014-11-06       Impact factor: 4.268

5.  [Long-term results after surgery for acute aortic endocarditis].

Authors:  P R Vogt; H P Brunner-Larocca
Journal:  Z Kardiol       Date:  2001-12

6.  Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone?

Authors:  K Truninger; C H Attenhofer Jost; B Seifert; P R Vogt; F Follath; A Schaffner; R Jenni
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

7.  Risk factors for short- and long-term survival in patients undergoing re-replacement due to prosthetic valve dysfunction.

Authors:  Bilgehan Savaş Oz; Hikmet Iyem; Hakki Tankut Akay; Cengiz Bolcal; Mehmet Yokusoglu; Erkan Kuralay; Ufuk Demirkilic; Harun Tatar
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

8.  Treatment of prosthetic valve endocarditis complicated by destruction of the aortic annulus.

Authors:  Yuki Okamoto; Kenji Minakata; Tomoyuki Yunoki; Masatake Katsu; Shin-ichiro Chino; Masahiko Matsumoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-08-18

9.  Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess.

Authors:  Kwan-Leung Chan
Journal:  CMAJ       Date:  2002-07-09       Impact factor: 8.262

10.  Surgical experience with infective endocarditis and aortic root abscess.

Authors:  Sak Lee; Byung-Chul Chang; Han Ki Park
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.